Cartesian Therapeutics (RNAC) Retained Earnings (2015 - 2026)

Cartesian Therapeutics (RNAC) has 12 years of Retained Earnings data on file, last reported at -$4.6 million in Q1 2026.

• On a quarterly basis, Retained Earnings changed 0.13% year-over-year to -$4.6 million in Q1 2026; TTM through Mar 2026 was -$4.6 million, a 0.13% change from a year earlier, with the FY2025 full-year figure at $700.7 million, up 1.57% from the prior year.
• Retained Earnings for Q1 2026 stood at -$4.6 million, down from $700.7 million in the prior quarter.
• Over the last five years, Retained Earnings for RNAC reached as high as $700.7 million in Q4 2025 and fell as low as -$729.8 million in Q3 2025.
• Historically, Retained Earnings has averaged $65.6 million across 5 years, with a median of -$4.6 million in 2026.
• On a YoY basis, Retained Earnings climbed as much as 15097.54% in 2024 and fell as far as 14670.75% in 2024.
• Year by year, Retained Earnings stood at $493.3 million in 2022, then sank by 100.93% to -$4.6 million in 2023, then jumped by 15097.54% to $689.9 million in 2024, then advanced by 1.57% to $700.7 million in 2025, then sank by 100.65% to -$4.6 million in 2026.
• Per Business Quant data, the three most recent Retained Earnings figures were -$4.6 million in Q1 2026, $700.7 million in Q4 2025, and -$729.8 million in Q3 2025.